WS #1253

The data dump reveals escalating geopolitical tensions in the Middle East as the primary market-moving signal, with Iran launching a new wave of missiles at Tel Aviv and central Israel, directly corroborating earlier reports. This development intensifies the risk-off environment, compounded by Iran's IRGC issuing direct warnings to US multinational corporations and banks in Gulf states, specifically naming Oracle, Honeywell, Lockheed Martin, and Halliburton as targets. The conflict's broadening impact is evident in oil prices, with $USO up 3%, and could drive volatility in defense, energy, and broader equity sectors over the next 1-8 hours. Corporate developments provide mixed signals amid the turmoil. JetBlue Airways lifted its Q1 guidance, with RASM now expected to increase 5.0%-7.0% versus prior guidance of 0.0%-4.0%, indicating stronger travel demand, while Delta Air Lines previously raised its outlook. However, this is offset by significant earnings misses from Telesat and GDS Holdings, and Rhythm Pharmaceuticals' Phase 3 trial failure, which led to a price target cut. The technology sector shows strength through AI collaborations, including CrowdStrike's expanded partnership with NVIDIA and positive sentiment trends for NVDA, SPY, and META, though these may be tempered by geopolitical risks. Biotechnology and healthcare sectors demonstrate resilience with multiple positive developments, including Eupraxia Pharmaceuticals reporting up to 76% remission in a study, Monte Rosa Therapeutics securing $345M in funding, and Gyre Therapeutics receiving priority review in China. However, Bicycle Therapeutics deprioritized its lead oncology program and cut its workforce by 30%, a negative signal. Other notable items include Amazon launching 1-hour delivery in hundreds of U.S. cities, potentially impacting retail and logistics, and China tightening listing rules for red chips in Hong Kong, which could create uncertainty for Chinese listings.